Sage Therapeutics, Inc. (NASDAQ:SAGE) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02.
On March 8, 2017, Howard Pien informed the Board of Directors (the “Board”) of Sage Therapeutics, Inc. (the “Company”) of his intention not to stand for re-election at the Company’s 2017 Annual Meeting of Shareholders (the “Annual Meeting”), and to retire from the Board effective immediately prior to the commencement of the Annual Meeting. Mr. Pien’s decision not to stand for reelection was not a result of any dispute or disagreement with the Company or the Board.
About Sage Therapeutics, Inc. (NASDAQ:SAGE)
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program. Sage Therapeutics, Inc. (NASDAQ:SAGE) Recent Trading Information
Sage Therapeutics, Inc. (NASDAQ:SAGE) closed its last trading session up +1.13 at 67.74 with 499,043 shares trading hands.
